低密度脂蛋白跨内皮细胞转运机制的研究进展

doi:10.11958/20251034

天津医药 ›› 2025, Vol. 53 ›› Issue (10): 1110-1115.doi: 10.11958/20251034

低密度脂蛋白跨内皮细胞转运机制的研究进展

赵树站¹(), 金冬霞¹^,²^,³, 李曦铭¹^,²^,³^,^△(), 郝天旭³, 陆艺蓓³

¹ 天津大学胸科医院心内科（邮编 300222）
² 天津市心血管急危重症重点实验室
³ 天津医科大学胸科临床学院心内科

收稿日期:2025-03-12 修回日期:2025-05-31 出版日期:2025-10-15 发布日期:2025-10-12
通讯作者: ^△E-mail：ljsunlight@126.com
作者简介:赵树站(2000)，男，硕士在读，主要从事心血管疾病方面研究。E-mail：z18839383512@163.com
基金资助:
天津市教委科研计划重点项目(2022YGZD01);天津市卫生健康科技项目(TJWJ2025MS035)

Research progress on the mechanism of low-density lipoprotein transendothelial transport

ZHAO Shuzhan¹(), JIN Dongxia¹^,²^,³, LI Ximing¹^,²^,³^,^△(), HAO Tianxu³, LU Yibei³

¹ Department of Chest Hospital of Tianjin University, Tianjin 300222, China
² Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care
³ Cardiology, Clinical College of Chest Medicine, Tianjin Medical University

Received:2025-03-12 Revised:2025-05-31 Published:2025-10-15 Online:2025-10-12
Contact: ^△E-mail：ljsunlight@126.com

赵树站, 金冬霞, 李曦铭, 郝天旭, 陆艺蓓. 低密度脂蛋白跨内皮细胞转运机制的研究进展[J]. 天津医药, 2025, 53(10): 1110-1115.

ZHAO Shuzhan, JIN Dongxia, LI Ximing, HAO Tianxu, LU Yibei. Research progress on the mechanism of low-density lipoprotein transendothelial transport[J]. Tianjin Medical Journal, 2025, 53(10): 1110-1115.

摘要/Abstract

摘要：

低密度脂蛋白（LDL）跨内皮细胞转运并在内皮下层积聚是动脉粥样硬化发生的核心环节。这一过程涉及多种受体和分子机制，这些机制共同调控LDL在内皮细胞中的转运以及其在血管壁的积累。除了受体介导的转运机制外，激素、炎症介质以及代谢产物等生理和病理因素也在其中扮演着重要角色。近年来的研究进一步阐明了这些因子在LDL转运中的关键调节功能，提示调控LDL跨膜转运有望成为预防早期动脉粥样硬化及治疗相关血管疾病的有效策略。该文综述相关研究进展，并探讨其在临床中的应用前景。

关键词: 脂蛋白类, LDL, 蛋白质转运, 动脉粥样硬化, 细胞因子类, 跨内皮细胞转运

Abstract:

The transendothelial transport of low-density lipoprotein (LDL) and its subendothelial accumulation represent a central pathogenic mechanism in atherogenesis. This process involves a variety of receptors and molecular mechanisms that work together to regulate the transport of LDL in endothelial cells and its accumulation in blood vessel wall. In addition to receptor-mediated transport mechanisms, physiological and pathological factors such as hormones, inflammatory mediators and metabolites also play an important role in it. Recent studies have further elucidated the critical regulatory roles of these factors in LDL transendothelial transport, suggesting that targeting LDL transcytosis may represent an effective strategy for the prevention of early atherosclerosis and the treatment of related vascular diseases. This review summarizes recent advances in this field and discusses their potential clinical applications.

Key words: lipoproteins, LDL, protein transport, atherosclerosis, cytokines, transendotheial transcytosis

中图分类号:

R543.5

图/表 1

参考文献 34

[1]	KANG H. Regulation of acetylation states by nutrients in the inhibition of vascular inflammation and atherosclerosis[J]. Int J Mol Sci, 2023, 24(11):9338. doi:10.3390/ijms24119338.
[2]	LIU T, ZHAO D, QI Y. Global trends in the epidemiology and management of dyslipidemia[J]. J Clin Med, 2022, 11(21):6377. doi:10.3390/jcm11216377.
[3]	LUCHETTI F, CRINELLI R, NASONI M G, et al. LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims?[J]. Br J Pharmacol, 2021, 178(16):3104-3114. doi:10.1111/bph.15272.
[4]	HONG D Y, LEE D H, LEE J Y, et al. Relationship between brain metabolic disorders and cognitive impairment:LDL receptor defect[J]. Int J Mol Sci, 2022, 23(15):8384. doi:10.3390/ijms23158384.
[5]	ZHOU Y X, WEI J, DENG G, et al. Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis[J]. Nat Cell Biol, 2023, 25(7):937-949. doi:10.1038/s41556-023-01160-6.
[6]	HU Y N, WU M, YU H P, et al. Analysis of low-density lipoprotein receptor gene mutations in a family with familial hypercholesterolemia[J]. PLoS One, 2024, 19(10):e0310547. doi:10.1371/journal.pone.0310547.
[7]	BOLANLE I O, DE LIEDEKERKE BEAUFORT G C, WEINBERG P D. Transcytosis of LDL across arterial endothelium:mechanisms and therapeutic targets[J]. Arterioscler Thromb Vasc Biol, 2025, 45(4):468-480. doi:10.1161/ATVBAHA.124.321549.
[8]	KRAEHLING J R, CHIDLOW J H, RAJAGOPAL C, et al. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells[J]. Nat Commun, 2016, 7:13516. doi:10.1038/ncomms13516.
[9]	TAO B, KRAEHLING J R, GHAFFARI S, et al. BMP-9 and LDL crosstalk regulates ALK1 endocytosis and LDL transcytosis in endothelial cells[J]. J Biol Chem, 2020, 295(52):18179-18188. doi:10.1074/jbc.RA120.015680.
[10]	LEE S, SCHLEER H, PARK H, et al. Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice[J]. Nat Cardiovasc Res, 2023, 2(5):438-448. doi:10.1038/s44161-023-00266-2.
[11]	HUANG L, CHAMBLISS K L, GAO X, et al. SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis[J]. Nature, 2019, 569(7757):565-569. doi:10.1038/s41586-019-1140-4.
[12]	FUNG K, HO T, XU Z, et al. Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1[J]. J Lipid Res, 2024, 65(4):100530. doi:10.1016/j.jlr.2024.100530.
[13]	TAO H, YANCEY P G, BLAKEMORE J L, et al. Macrophage SR-BI modulates autophagy via VPS34 complex and PPARα transcription of Tfeb in atherosclerosis[J]. J Clin Invest, 2021, 131(7):e94229. doi:10.1172/JCI94229.
[14]	PUDDU A, MONTECUCCO F, MAGGI D. Caveolin-1 and atherosclerosis: regulation of LDLs fate in endothelial cells[J]. Int J Mol Sci, 2023, 24(10):8869. doi:10.3390/ijms24108869.
[15]	SHU Y, JIN S. Caveolin-1 in endothelial cells:A potential therapeutic target for atherosclerosis[J]. Heliyon, 2023, 9(8):e18653. doi:10.1016/j.heliyon.2023.e18653.
[16]	ZHANG Y, JIA X, WANG Y, et al. Caveolin-1-mediated LDL transcytosis across endothelial cells in atherosclerosis[J]. Atherosclerosis, 2025, 402:119113. doi:10.1016/j.atherosclerosis.2025.119113.
[17]	WANG D X, PAN Y Q, LIU B, et al. Cav-1 promotes atherosclerosis by activating JNK-associated signaling[J]. Biochem Biophys Res Commun, 2018, 503(2):513-520. doi:10.1016/j.bbrc.2018.05.036.
[18]	ZHU L, LIAO Y, JIANG B. Role of ROS and autophagy in the pathological process of atherosclerosis[J]. J Physiol Biochem, 2024, 80(4):743-756. doi:10.1007/s13105-024-01039-6.
[19]	YERLY A, VAN DER VORST E, BAUMGARTNER I, et al. Sex-specific and hormone-related differences in vascular remodelling in atherosclerosis[J]. Eur J Clin Invest, 2023, 53(1):e13885. doi:10.1111/eci.13885.
[20]	YANG J, XU M, WANG Z, et al. Unraveling estrogen and PCSK9's roles in lipid metabolism disorders among ovariectomized mice[J]. Reprod Sci, 2025, 32(2):316-325. doi:10.1007/s43032-024-01614-8.
[21]	QIAN C, LIU J, LIU H. Targeting estrogen receptor signaling for treating heart failure[J]. Heart Fail Rev, 2024, 29(1):125-131. doi:10.1007/s10741-023-10356-9.
[22]	GHAFFARI S, NADERI NABI F, SUGIYAMA M G, et al. Estrogen inhibits LDL (low-density lipoprotein)transcytosis by human coronary artery endothelial cells via GPER (G-protein-coupled estrogen receptor) and SR-BI (scavenger receptor class b type 1)[J]. Arterioscler Thromb Vasc Biol, 2018, 38(10):2283-2294. doi:10.1161/ATVBAHA.118.310792.
[23]	XIE F, LI X, XU Y, et al. Estrogen mediates an atherosclerotic-protective action via estrogen receptor alpha/SREBP-1 signaling[J]. Front Cardiovasc Med, 2022, 9:895916. doi:10.3389/fcvm.2022.895916.
[24]	HUO X, SU B, QIN G, et al. HMGB1 promotes Ox-LDL-induced endothelial cell damage by inhibiting PI3K/Akt signaling pathway[J]. BMC Cardiovasc Disord, 2022, 22(1):555. doi:10.1186/s12872-022-03003-y.
[25]	GHAFFARI S, JANG E, NADERINABI F, et al. Endothelial HMGB1 is a critical regulator of LDL transcytosis via an SREBP2-SR-BI axis[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1):200-216. doi:10.1161/ATVBAHA.120.314557.
[26]	RUBINELLI L, MANZO O L, SUNGHO J, et al. Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases[J]. Nat Commun, 2025, 16(1):1968. doi:10.1038/s41467-025-56869-9.
[27]	VELAGAPUDI S, WANG D, POTI F, et al. Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways[J]. Cardiovasc Res, 2024, 120(5):476-489. doi:10.1093/cvr/cvad183.
[28]	JIA X, BAI X, YANG X, et al. VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis[J]. Metabolism, 2022, 135:155274. doi:10.1016/j.metabol.2022.155274.
[29]	FRANSÉN K, PETTERSSON C, HURTIG-WENNLÖF A. CRP levels are significantly associated with CRP genotype and estrogen use in the lifestyle,biomarker and atherosclerosis (LBA) study[J]. BMC Cardiovasc Disord, 2022, 22(1):170. doi:10.1186/s12872-022-02610-z.
[30]	BIAN F, YANG X Y, XU G, et al. CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells[J]. Front Pharmacol, 2019, 10:40. doi:10.3389/fphar.2019.00040.
[31]	BIAN F, CUI J, ZHENG T, et al. Reactive oxygen species mediate angiotensin II-induced transcytosis of low-density lipoprotein across endothelial cells[J]. Int J Mol Med, 2017, 39(3):629-635. doi:10.3892/ijmm.2017.2887.
[32]	MANSOUR A, MOUSA M, ABDELMANNAN D, et al. Microvascular and macrovascular complications of type 2 diabetes mellitus:Exome wide association analyses[J]. Front Endocrinol (Lausanne), 2023, 14:1143067. doi:10.3389/fendo.2023.1143067.
[33]	BAI X, YANG X, JIA X, et al. CAV1-CAVIN1-LC3B-mediated autophagy regulates high glucose-stimulated LDL transcytosis[J]. Autophagy, 2020, 16(6):1111-1129. doi:10.1080/15548627.2019.1659613.
[34]	SUN H, MA X, MA H, et al. High glucose levels accelerate atherosclerosis via NLRP3-IL/ MAPK/NF-κB-related inflammation pathways[J]. Biochem Biophys Res Commun, 2024, 704:149702. doi:10.1016/j.bbrc.2024.149702.

低密度脂蛋白跨内皮细胞转运机制的研究进展

Research progress on the mechanism of low-density lipoprotein transendothelial transport

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒋苏, 李东霞, 吕新翔, 崔艳红, 吕李婷. 基于PI3K/Akt/NF-κB信号通路探讨黄连素对特应性皮炎大鼠皮肤病理变化的治疗作用[J]. 天津医药, 2025, 53(7): 679-683.
[2]	邓子昊, 黄欣扬, 钟坤江, 赵博. 纳米材料在动脉粥样硬化性心血管疾病中的应用进展[J]. 天津医药, 2025, 53(5): 556-560.
[3]	胡紫月, 郑茹瑜, 刘丹, 唐姗, 阚艳敏, 经翔, 李倩. 颈动脉粥样硬化斑块近心端角度与新生血管评分对脑梗死的预测价值[J]. 天津医药, 2025, 53(4): 439-443.
[4]	吕婧, 朱方颖, 朱凯, 李云, 杨娜, 温淑云, 仲米倩. 类风湿关节炎患者动脉粥样硬化风险预测模型的构建与验证[J]. 天津医药, 2025, 53(10): 1043-1047.
[5]	金佳纯, 陆彩霞, 吴燕君. 中性粒细胞胞外诱捕网对动脉粥样硬化性心血管病的作用机制及其研究进展[J]. 天津医药, 2025, 53(10): 1104-1109.
[6]	天津市医学会神经外科学分会. 颅外段颈部动脉粥样硬化性疾病外科治疗京津冀专家共识[J]. 天津医药, 2024, 52(3): 225-230.
[7]	谷巍, 张惠娜, 侯丽萍, 于敏, 程黎蓉. 脂质相关指数与糖尿病肾病相关性研究[J]. 天津医药, 2024, 52(12): 1308-1312.
[8]	张贵婷, 何超. oxLDL/β2GPⅠ/aβ2GPⅠ复合物通过TLR4/MyD88/NF-κB途径促进血管内皮细胞血管生成[J]. 天津医药, 2024, 52(11): 1131-1136.
[9]	刘艳文, 刘水清, 林少伟, 刘协红. 毛蕊花糖苷调节HMGB1/RAGE/NF-κB信号通路对动脉粥样硬化大鼠内皮功能障碍的影响[J]. 天津医药, 2023, 51(12): 1339-1343.
[10]	王海娇, 何红美, 祁麟, 崔玉娇, 肖春辉, 王毅. 沉默T-cadherin对ox-LDL诱导人绒毛膜滋养层细胞HTR-8/SVneo生物学行为的影响[J]. 天津医药, 2023, 51(1): 8-13.
[11]	朱云林, 殷广莉, 戴平涛. 颈动脉超声及血清HbA1c、FIB对急性前循环脑梗死的评估价值分析[J]. 天津医药, 2022, 50(9): 948-952.
[12]	王华, 何雄. 护心通络方通过干预CETP介导脂质代谢抗兔动脉粥样硬化的实验研究[J]. 天津医药, 2022, 50(8): 827-831.
[13]	李春霞, 杨志明, 李俊, 卜星彭. 老年慢性心力衰竭患者血清LDLR、DNM2水平及临床意义[J]. 天津医药, 2022, 50(7): 766-770.
[14]	林玉凤, 汪志云, 王雪松△. 丁苯酞下调血清脂蛋白相关磷脂酶A2改善急性大动脉#br# 粥样硬化型脑梗死患者预后的临床观察#br#[J]. 天津医药, 2022, 50(5): 544-547.
[15]	胡明哲, 陈香岩, 吴光亮, 乔利军, 蔡业锋△. 中性粒细胞淋巴细胞比值、淋巴细胞单核细胞比值与症状性颅内动脉粥样硬化性狭窄的关系#br#[J]. 天津医药, 2022, 50(5): 493-497.